Next Article in Journal
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
Next Article in Special Issue
Detoxified O-Specific Polysaccharide (O-SP)–Protein Conjugates: Emerging Approach in the Shigella Vaccine Development Scene
Previous Article in Journal
In Search of a Lost Father: Adrien Proust (1834–1903), An Almost Forgotten Public Health Pioneer
Previous Article in Special Issue
From Concept to Clinical Product: A Brief History of the Novel Shigella Invaplex Vaccine’s Refinement and Evolution
 
 
Review

Article Versions Notes

Vaccines 2022, 10(5), 645; https://doi.org/10.3390/vaccines10050645
Action Date Notes Link
article xml file uploaded 20 April 2022 09:45 CEST Original file -
article xml uploaded. 20 April 2022 09:45 CEST Update https://www.mdpi.com/2076-393X/10/5/645/xml
article pdf uploaded. 20 April 2022 09:45 CEST Version of Record https://www.mdpi.com/2076-393X/10/5/645/pdf
article supplementary file uploaded. 20 April 2022 09:45 CEST - https://www.mdpi.com/2076-393X/10/5/645#supplementary
article html file updated 20 April 2022 09:46 CEST Original file -
article html file updated 2 August 2022 19:47 CEST Update https://www.mdpi.com/2076-393X/10/5/645/html
Back to TopTop